Driessen A, Ectors N, Creemers J, Filez L, Penninckx F, Van Cutsem E, Geboes K
Department of Pathology, University Hospitals KU Leuven, Belgium.
Eur J Gastroenterol Hepatol. 1998 Jul;10(7):595-600. doi: 10.1097/00042737-199807000-00013.
Intestinal metaplasia is associated with gastric carcinomas, in particular intestinal-type carcinomas. According to the literature, intestinal metaplasia, especially the sulphomucin-rich incomplete type (type IIb or III) can be considered as a precancerous lesion. Intestinal metaplasia is not uncommon in gastric lymphomas, and the purpose of this study was to determine its prevalence and extent, its different subtypes and the distribution of sulphomucin and to compare these findings with those in gastric carcinomas.
The prevalence and grade of intestinal metaplasia were investigated in surgical specimens from 160 patients with gastric carcinoma (102) [intestinal type (69), diffuse type (33)] and gastric lymphoma (58) [marginal zone cell (29), diffuse large cell (29)]. Intestinal metaplasia is analysed by specific mucin stains.
Intestinal metaplasia was described according to the Updated Sydney system. Using periodic acid-Schiff Alcian Blue pH 2.5 and high iron-diamine/Alcian Blue staining, the intestinal metaplasia was classified (Jass classification) and its sulphomucin content was determined.
The prevalence and extent of intestinal metaplasia are significantly higher in intestinal-type carcinomas than all other gastric malignancies. Subtyping of intestinal metaplasia is independent of the different types of gastric neoplasia. High sulphomucin positivity in the metaplastic epithelium is only seen in intestinal-type carcinomas, although in a small number of cases (21.5%).
Prevalence, extent and sulphomucin content of intestinal metaplasia are significantly higher in intestinal-type gastric carcinoma compared to diffuse-type carcinoma, marginal zone cell and diffuse large cell lymphomas in the stomach.
肠化生与胃癌相关,尤其是肠型癌。根据文献,肠化生,特别是富含硫酸黏液素的不完全型(IIb型或III型)可被视为一种癌前病变。肠化生在胃淋巴瘤中并不少见,本研究的目的是确定其患病率和范围、不同亚型以及硫酸黏液素的分布,并将这些结果与胃癌的结果进行比较。
对160例胃癌患者(102例)[肠型(69例),弥漫型(33例)]和胃淋巴瘤患者(58例)[边缘区细胞型(29例),弥漫大细胞型(29例)]的手术标本进行肠化生患病率和分级的调查。通过特异性黏液染色分析肠化生。
根据更新的悉尼系统描述肠化生。使用过碘酸希夫阿尔辛蓝pH 2.5和高铁二胺/阿尔辛蓝染色对肠化生进行分类(贾斯分类)并确定其硫酸黏液素含量。
肠化生的患病率和范围在肠型癌中显著高于所有其他胃恶性肿瘤。肠化生的亚型与胃肿瘤的不同类型无关。化生上皮中高硫酸黏液素阳性仅在肠型癌中可见,尽管在少数病例(21.5%)中出现。
与弥漫型癌、胃边缘区细胞淋巴瘤和弥漫大细胞淋巴瘤相比,肠型胃癌中肠化生的患病率、范围和硫酸黏液素含量显著更高。